Press Release: FILAMENT HEALTH IS ISSUED PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE
CANNANNEW REPORT
VANCOUVER, BC, April 13, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a patent by the United States Patent and Trademark Office (USPTO) for the extraction and standardization of natural psilocybin and associated psychedelic compounds. The patent describes essential technology for transforming variable psychedelic raw materials into pharmaceutical-grade, standardized drug candidates. "The issuance of Filament's first US patent is a testament to the strength of our drug development platform," said Benjamin Lightburn, Chief Executive Officer. "This approval represents important progress for our intellectual property portfolio." Filament has developed innovative technology to extract and standardize stable doses of natural compounds from magic mushrooms. Previous methods of natural extraction have experienced challenges relating to low yields, instability, and a lack of repeatability. "This latest achievement continues our 100% pending-to-issued patent success rate ahead of schedule and under budget," said Taran Grey, Director of Intellectual Property. "Shepherding an application to issuance is different in every country, therefore having our IP validated by more than one government is evidence of our team's talent for innovation by truly diverse criteria." Filament currently holds multiple patents, including the first-ever patent for the industrial extraction and standardization of natural psilocybin, which was issued on August 3, 2021. ABOUT FILAMENT HEALTH (OTCQB: FLHLF ) (NEO:FH ) (FSE:7QS ) Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates. Learn more at www.filament.health and on Twitter, Instagram and LinkedIn.
Excerpt only ...
READ MORE BELOW
Source : Press Release: FILAMENT HEALTH IS ISSUED PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE
reposted by Cannabis News World
No comments:
Post a Comment